Alternative Cell Sources to Adult Hepatocytes for Hepatic Cell Therapy.
Adult hepatocyte transplantation is limited by scarce availability of suitable donor liver tissue for hepatocyte isolation. New cell-based therapies are being developed to supplement whole-organ liver transplantation, to reduce the waiting-list mortality rate, and to obtain more sustained and significant metabolic correction. Fetal livers and unsuitable neonatal livers for organ transplantation have been proposed as potential useful sources of hepatic cells for cell therapy. However, the major challenge is to use alternative cell sources for transplantation that can be derived from reproducible methods. Different types of stem cells with hepatic differentiation potential are eligible for generating large numbers of functional hepatocytes for liver cell therapy to treat degenerative disorders, inborn hepatic metabolic diseases, and organ failure. Clinical trials are designed to fully establish the safety profile of such therapies and to define target patient groups and standardized protocols.
Unidad de Cirugıa Hepato-Bilio-Pancreatica y Trasplante Hepatico, Hospital Universitario y Politécnico La Fe de Valencia, Avenida Fernando Abril Martorel 106, 46026, Valencia, Spain. pareja_eug@gva.es.|Unidad de Terapia Celular Hepática, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, 46026, Valencia, Spain. pareja_eug@gva.es.
Eugenia
E
Pareja
Unidad de Terapia Celular Hepática, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, 46026, Valencia, Spain.|Unidad de Hepatologıa Experimental, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, 46026, Valencia, Spain.|CIBERehd, FIS, Barcelona, 08036, Spain.
María José
MJ
Gómez-Lechón
Unidad de Terapia Celular Hepática, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, 46026, Valencia, Spain.|Unidad de Hepatologıa Experimental, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, 46026, Valencia, Spain.
Laia
L
Tolosa
D000293:Adolescent; D000328:Adult; D000368:Aged; D002454:Cell Differentiation; D017690:Cell Transplantation / Q000379:methods* / Q000639:trends; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D015925:Cryopreservation / Q000379:methods*; D005260:Female; D005333:Fetus / Q000166:cytology; D022781:Hepatocytes / Q000502:physiology / Q000637:transplantation*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008099:Liver / Q000166:cytology / Q000378:metabolism; D008107:Liver Diseases / Q000601:surgery*; D016031:Liver Transplantation / Q000379:methods; D008297:Male; D008875:Middle Aged; D013234:Stem Cells / Q000502:physiology*; D014019:Tissue Donors; D014850:Waiting Lists / Q000401:mortality; D055815:Young Adult
Clinical trials; Fetal hepatocytes; Hepatocyte transplantation; Inborn metabolic errors; Induced pluripotent stem cells; Liver transplantation; Neonatal hepatocytes; Pluripotent stem cells